APPLICABILITY OF GLP-1 RECEPTOR AGONISTS IN REFRACTORY IMMUNE-MEDIATED DERMATOLOGICAL DISEASES: THERAPEUTIC PERSPECTIVES IN PSORIASIS

Abstract

This study reviewed the literature on the applicability of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the treatment of psoriasis. The objective was to analyze their anti-inflammatory effects, patient profiles, and therapeutic perspectives. The methodology consisted of a literature review conducted in the PubMed/MEDLINE and BVS databases, using English descriptors for psoriasis and GLP-1RAs, focusing on full-text articles published in the last five years and excluding studies not related to the main objective. Additional reference dermatology literature was also consulted. The results indicate that GLP-1RAs have therapeutic potential in psoriasis, exerting direct anti-inflammatory effects through inhibition of inflammatory pathways, activation of cytoprotective mechanisms, and metabolic modulation. A significant reduction in skin lesions and improvement in quality of life were observed, particularly in patients with comorbidities such as obesity and type 2 diabetes, as assessed by specific clinical scores. It is concluded that GLP-1RAs represent a promising therapeutic option for psoriasis, especially in refractory cases. However, large-scale and robust clinical trials are still required to confirm their safety, long-term efficacy, and to define the ideal patient profile.